425 related articles for article (PubMed ID: 25755608)
41. Percutaneous ethanol injection is an acceptable bridging therapy to hepatocellular carcinoma prior to liver transplantation.
Lazzarotto-da-Silva G; Grezzana-Filho TJM; Scaffaro LA; Farenzena M; Silva RK; de Araujo A; Arruda S; Feier FH; Prediger L; Lazzaretti GS; Alvares-da-Silva MR; Chedid AD; Kruel CRP; Chedid MF
Langenbecks Arch Surg; 2023 Jan; 408(1):26. PubMed ID: 36639606
[TBL] [Abstract][Full Text] [Related]
42. Gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid-enhanced magnetic resonance imaging for evaluating fibrosis regression in chronic hepatitis C patients after direct-acting antiviral.
Li XH; Huang R; Yang M; Wang J; Gao YH; Jin Q; Ma DL; Wei L; Rao HY
World J Gastroenterol; 2022 May; 28(20):2214-2226. PubMed ID: 35721884
[TBL] [Abstract][Full Text] [Related]
43. Multimodal therapy for hepatocellular carcinoma: a complementary approach to liver transplantation.
Schumacher PA; Powell JJ; MacNeill AJ; Buczkowski AK; Erb SR; Ho SG; Scudamore CH; Steinbrecher UP; Weiss A; Yoshida E; Chung SW
Ann Hepatol; 2010; 9(1):23-32. PubMed ID: 20308719
[TBL] [Abstract][Full Text] [Related]
44. Tissue diagnosis of hepatocellular carcinoma.
Jain D
J Clin Exp Hepatol; 2014 Aug; 4(Suppl 3):S67-73. PubMed ID: 25755614
[TBL] [Abstract][Full Text] [Related]
45. Living donor liver transplantation for hepatocellular carcinoma.
Lee SG; Moon DB
Recent Results Cancer Res; 2013; 190():165-79. PubMed ID: 22941020
[TBL] [Abstract][Full Text] [Related]
46. Post-ablation des-gamma-carboxy prothrombin level predicts prognosis in hepatitis B-related hepatocellular carcinoma.
Lee S; Rhim H; Kim YS; Kang TW; Song KD
Liver Int; 2016 Apr; 36(4):580-7. PubMed ID: 26503910
[TBL] [Abstract][Full Text] [Related]
47. Radio frequency ablation for primary liver cancer: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2004; 4(8):1-50. PubMed ID: 23074458
[TBL] [Abstract][Full Text] [Related]
48. SQSTM1 Expression in Hepatocellular Carcinoma and Relation to Tumor Recurrence After Radiofrequency Ablation.
Abdel-Moety A; Baddour N; Salem P; El-Tobgy H; El-Shendidi A
J Clin Exp Hepatol; 2022; 12(3):774-784. PubMed ID: 35677515
[TBL] [Abstract][Full Text] [Related]
49. Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study.
Ren Y; Cao Y; Ma H; Kan X; Zhou C; Liu J; Shi Q; Feng G; Xiong B; Zheng C
BMC Cancer; 2019 Oct; 19(1):983. PubMed ID: 31640620
[TBL] [Abstract][Full Text] [Related]
50. Transarterial chemoembolization in patients with hepatocellular carcinoma beyond Barcelona-Clinic Liver Cancer- B and portal vein tumor thrombosis: Experience from a tertiary care center.
Anand S; Pottakkat B; Raja K; Chandrasekar S; Satheesh S
Indian J Cancer; 2022; 59(3):325-329. PubMed ID: 33753610
[TBL] [Abstract][Full Text] [Related]
51. Role of Contrast-Enhanced Ultrasound as a Second-Line Diagnostic Modality in Noninvasive Diagnostic Algorithms for Hepatocellular Carcinoma.
Kang HJ; Lee JM; Yoon JH; Han JK
Korean J Radiol; 2021 Mar; 22(3):354-365. PubMed ID: 33236540
[TBL] [Abstract][Full Text] [Related]
52. Non-Hypervascular Hypointense Hepatic Nodules during the Hepatobiliary Phase of Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic Acid-Enhanced MRI as a Risk Factor of Intrahepatic Distant Recurrence after Radiofrequency Ablation of Hepatocellular Carcinoma.
Iwamoto T; Imai Y; Igura T; Kogita S; Sawai Y; Fukuda K; Yamaguchi Y; Matsumoto Y; Nakahara M; Morimoto O; Ohashi H; Fujita N; Kudo M; Takehara T
Dig Dis; 2017; 35(6):574-582. PubMed ID: 29040990
[TBL] [Abstract][Full Text] [Related]
53. Survival benefit of patients with inoperable hepatocellular carcinoma treated by a combination of transarterial chemoembolization and percutaneous ethanol injection--a single-center analysis including 132 patients.
Allgaier HP; Deibert P; Olschewski M; Spamer C; Blum U; Gerok W; Blum HE
Int J Cancer; 1998 Dec; 79(6):601-5. PubMed ID: 9842968
[TBL] [Abstract][Full Text] [Related]
54. Non-alcoholic Fatty Liver Disease and Metabolic Syndrome-Position Paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology.
Duseja A; Singh SP; Saraswat VA; Acharya SK; Chawla YK; Chowdhury S; Dhiman RK; Jayakumar RV; Madan K; Misra SP; Mishra H; Modi SK; Muruganathan A; Saboo B; Sahay R; Upadhyay R
J Clin Exp Hepatol; 2015 Mar; 5(1):51-68. PubMed ID: 25941433
[TBL] [Abstract][Full Text] [Related]
55. Hepatitis B Virus Infection can Cause Hepatocellular Carcinoma in Less Advanced Liver Cirrhosis: A Comparative Study of 142 Patients from North India.
Arora A; Sharma P; Tyagi P; Singla V; Arora V; Bansal N; Toshniwal J; Kumar A
J Clin Exp Hepatol; 2013 Dec; 3(4):288-95. PubMed ID: 25755516
[TBL] [Abstract][Full Text] [Related]
56. Living donor liver transplantation for hepatocellular carcinoma achieves better outcomes.
Lin CC; Chen CL
Hepatobiliary Surg Nutr; 2016 Oct; 5(5):415-421. PubMed ID: 27826556
[TBL] [Abstract][Full Text] [Related]
57. Presence of non-hypervascular hypointense nodules on Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging in patients with hepatocellular carcinoma.
Inoue M; Ogasawara S; Chiba T; Ooka Y; Wakamatsu T; Kobayashi K; Suzuki E; Tawada A; Yokosuka O
J Gastroenterol Hepatol; 2017 Apr; 32(4):908-915. PubMed ID: 27787908
[TBL] [Abstract][Full Text] [Related]
58. Comparison of Contrast-Enhanced Ultrasound and Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic Acid-Enhanced MRI for the Diagnosis of Macroscopic Type of Hepatocellular Carcinoma.
Iwamoto T; Imai Y; Kogita S; Igura T; Sawai Y; Fukuda K; Yamaguchi Y; Matsumoto Y; Nakahara M; Morimoto O; Seki Y; Ohashi H; Fujita N; Kudo M; Takehara T
Dig Dis; 2016; 34(6):679-686. PubMed ID: 27750237
[TBL] [Abstract][Full Text] [Related]
59. Prognostic nomogram for hepatocellular carcinoma patients after transarterial chemoembolization based on des-γ-carboxy prothrombin reactivity and modified Response Evaluation Criteria in Solid Tumors.
Zhao SM; Qiu LW; Zhao H; Gu WW; Yang XH; Gu ZX; Shi RF; Ni CF
J Cancer Res Ther; 2021 Jul; 17(3):707-714. PubMed ID: 34269303
[TBL] [Abstract][Full Text] [Related]
60. Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study.
Zhang L; Sun JH; Ji JS; Zhong BY; Zhou GH; Song JJ; Hou ZH; Huang P; Zhang S; Li Z; Zhu XL; Ni CF
AJR Am J Roentgenol; 2021 Oct; 217(4):933-943. PubMed ID: 33245680
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
